Alteration of the m(6)A methylation landscape in a mouse model of scleroderma

Liangliang Shen,Yue Yu,Miao Jiang,Jingjun Zhao
DOI: https://doi.org/10.2217/epi-2021-0369
2021-01-01
Epigenomics
Abstract:Aim: To explore the N-6-methyladenosine (m(6)A) methylation of mRNAs and its roles in a mouse model of scleroderma. Materials & methods: To evaluate whether the mouse model of scleroderma could meet the experimental requirements, we examined skin tissue specimens by pathological staining and identified the related indicators by quantitative (qPCR). m(6)A-tagged mRNAs were identified via m(6)A epitranscriptomic microarray, and m(6)A-RNA-immunoprecipitation qPCR and qPCR were performed to confirm microarray data. Results: There were differences in m(6)A methylation among 843 mRNAs. Further, there were significant differences among Hras, Saa1, Ccl3, Ccl9 and Il1b in terms of methylation and expression. Conclusion: The m(6)A methylation spectrum in a mouse model of scleroderma may explain the occurrence of scleroderma. Lay abstract Scleroderma is an autoimmune disease with an unknown etiology. At present there is no effective treatment, and the prognosis is poor. Although m(6)A methylation is the most common RNA modification and affects cell biological function by influencing mRNA expression levels, the role of m(6)A methylation in scleroderma is unknown. Based on a mouse model of scleroderma, we screened and validated mRNAs related to m(6)A regulation, including Hras, Lama3, Stat3, Tnc, Ccl3, Ccl9, Saa1 and Il1b. While the results are encouraging, they are only preliminary. We plan to explore the altered pattern of m(6)A methylation in skin specimens from patients with scleroderma. This study is important for developing biomarkers for diagnosis and treatment of scleroderma in the future.
What problem does this paper attempt to address?